PPARgamma activation: a potential treatment for pulmonary hypertension.
about
Pulmonary hypertension in patients with heart failure and preserved ejection fraction: differential diagnosis and managementInterdisciplinary networks for the treatment of childhood pulmonary vascular disease: what pulmonary hypertension doctors can learn from pediatric oncologistsNew perspectives for the treatment of pulmonary hypertensionThe microRNA-130/301 family controls vasoconstriction in pulmonary hypertensionImpaired right ventricular hemodynamics indicate preclinical pulmonary hypertension in patients with metabolic syndrome.Impact of diabetes in patients with pulmonary hypertensionHypoxia induces downregulation of PPAR-γ in isolated pulmonary arterial smooth muscle cells and in rat lung via transforming growth factor-β signaling.Design and validation of an endothelial progenitor cell capture chip and its application in patients with pulmonary arterial hypertensionPeroxisome proliferator-activated receptor γ: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosisRegulation of Matrix Remodeling by Peroxisome Proliferator-Activated Receptor-γ: A Novel Link Between Metabolism and Fibrogenesis.Metabolic Dysfunction in Pulmonary Arterial Hypertension.Reactive oxygen and nitrogen species in pulmonary hypertension.Hyperoxia synergizes with mutant bone morphogenic protein receptor 2 to cause metabolic stress, oxidant injury, and pulmonary hypertension.Rosiglitazone Attenuated Endothelin-1-Induced Vasoconstriction of Pulmonary Arteries in the Rat Model of Pulmonary Arterial Hypertension via Differential Regulation of ET-1 Receptors.Pediatric pulmonary arterial hypertension: current and emerging therapeutic options.A process-based review of mouse models of pulmonary hypertension.Fenfluramine-induced gene dysregulation in human pulmonary artery smooth muscle and endothelial cellsSystems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension.Role of Transcription Factors in Pulmonary Artery Smooth Muscle Cells: An Important Link to Hypoxic Pulmonary Hypertension.Repurposing rosiglitazone, a PPAR-γ agonist and oral antidiabetic, as an inhaled formulation, for the treatment of PAH.Pulmonary Arterial Hypertension and Insulin Resistance.Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice.Prenatal treatment with rosiglitazone attenuates vascular remodeling and pulmonary monocyte influx in experimental congenital diaphragmatic hernia
P2860
Q26750994-23B05CBA-EFEB-487B-B259-CAAED7DB0B14Q26860314-6584AD1C-CBE9-4A3A-9786-89481DE3388FQ34903204-09CBA87F-C336-42A3-BAB2-13BFD46B46E8Q35002833-C9B6180D-5308-4D06-AED9-0D0E2106A468Q35354138-2978FA83-70D3-4E64-9E5D-C7A102538DB2Q35517404-FA667994-9BBF-418F-A246-DFDFC3DDEC62Q35601455-AB78DCE9-B0F0-4661-A030-030216B1EEC1Q35835947-C396C19A-BAC7-415A-B65D-CD12BB67F271Q35954579-3183B99C-9957-4415-BA1E-36E3CE2F51B7Q36093802-34C2BF55-540B-4F33-AB51-D0B660447495Q36825335-7DF73505-B477-41CA-87C4-E14185410EAFQ37376997-8CA8C1EC-2236-42A2-8880-6430E600B5BAQ37596437-2911B520-0B3D-4FAC-B3AE-F3183CBA3CB0Q37632333-9AF995DA-11EB-469B-B787-7A70023DFE36Q37879213-0BF08382-6A9E-49B9-9503-85DAF488E95AQ38078369-1C9D8E74-CA6D-4DCF-BD82-0F21AC5A7B88Q39385317-79D446B4-4DDC-4EF6-BC1F-633D5955A358Q42746715-B8EAD0FD-680A-447D-B65D-E701E91F6DF5Q46280906-DDA08A3F-5100-45BB-AD07-132817FBD9D8Q53686493-7C46E614-F63D-4866-B1D0-80ED905ED36DQ54946092-3E88DCF1-5BF2-410F-BC52-7C0339142625Q55112828-854FFF8B-8619-4DDC-999D-0C69E3B10E76Q59136832-6A858930-0489-47EC-8B65-30D036A422BF
P2860
PPARgamma activation: a potential treatment for pulmonary hypertension.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
PPARgamma activation: a potential treatment for pulmonary hypertension.
@en
PPARgamma activation: a potential treatment for pulmonary hypertension.
@nl
type
label
PPARgamma activation: a potential treatment for pulmonary hypertension.
@en
PPARgamma activation: a potential treatment for pulmonary hypertension.
@nl
prefLabel
PPARgamma activation: a potential treatment for pulmonary hypertension.
@en
PPARgamma activation: a potential treatment for pulmonary hypertension.
@nl
P2860
P1476
PPARgamma activation: a potential treatment for pulmonary hypertension.
@en
P2093
Georg Hansmann
Roham T Zamanian
P2860
P304
P356
10.1126/SCITRANSLMED.3000267
P407
P577
2009-12-01T00:00:00Z